– USA, CA – Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced the appointment of Dr. Ray Sanchez (M.D.) to its Board of Directors, effective August 12, 2025.
About Dr. Raymond Sanchez
Dr. Ray Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industry.
Dr. Ray Sanchez has served as a Senior Advisor at Bain Capital Life Sciences, a global investment firm, since September 2024. He served as CMO of Cerevel Therapeutics Holdings, Inc. (previously Nasdaq: CERE), a biopharmaceutical company, from January 2019 to August 2024, when it was acquired by AbbVie Inc.
From November 2007 to January 2019, Dr. Ray Sanchez held various roles of increasing responsibility at Otsuka Pharmaceutical Development & Commercialization, Inc., a privately-held healthcare company, most recently as SVP, Global Clinical Development, beginning in November 2013. From June 2018 to January 2019, he served as CMO of Avanir Pharmaceuticals, Inc., a pharmaceutical company (later acquired by Otsuka America Pharmaceutical, Inc.). Dr. Sanchez has served as a member of the board of directors of Rapport Therapeutics, Inc. (Nasdaq: RAPP) since November 2024. He also serves on the board of directors of numerous privately held biotechnology companies.
Before joining the life sciences industry, Dr. Ray Sanchez trained in psychiatry at the Yale School of Medicine he where he was Chief Resident as well as a fellow and an instructor. Dr. Sanchez was an executive co-chair of the International Society for CNS Drug Development from November 2017 to January 2022 and has also contributed to other academic and charitable organizations, such as the Connecticut Mental Health Center Foundation and Yale School of Medicine.
Dr. Ray Sanchez holds two degrees from Northwestern University: a Bachelor of Arts degree in psychology from the Weinberg College of Arts and Sciences and a medical degree from the Feinberg School of Medicine.
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in bipolar depression, major depressive disorder, treatment-resistant depression, and schizophrenia, and other mental health conditions.
For more: https://altoneuroscience.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.